Roche Partners with Blueprint Medicine on Cancer ImmunotherapyBlueprint Medicines said today it is launching a $1 billion-plus collaboration with Roche to discover, develop, and commercialize up to five small-molecule therapeutics targeting kinases deemed important in cancer immunotherapy.
The five candidates could be either single products or products to be combined with Roche therapeutics.
Roche will hold options triggered upon achievement of Phase I proof-of-concept for an exclusive license to each drug candidate developed under the collaboration.
Blueprint Medicines will primarily oversee preclinical research and clinical development for each program before Roche exercises any option for it. Should Roche exercise an option for a program, Roche will be responsible for global development for that program through Phase III clinical trials.
Full article available at Gen.